Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration
- 29 October 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of Autoimmunity
- Vol. 21 (3) , 283-293
- https://doi.org/10.1016/s0896-8411(03)00113-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- TH1 AND TH2 RESPONSES IN PATHOGENESIS AND REGULATION OF EXPERIMENTAL AUTOIMMUNE UVEORETINITISInternational Reviews of Immunology, 2002
- Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panelAmerican Journal of Ophthalmology, 2000
- Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasisJournal of the American Academy of Dermatology, 2000
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationNew England Journal of Medicine, 1998
- Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.The Journal of Experimental Medicine, 1996
- Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assayJournal of Immunological Methods, 1995
- A humanized antibody that binds to the interleukin 2 receptor.Proceedings of the National Academy of Sciences, 1989
- PROLONGATION OF PRIMATE RENAL ALLOGRAFT SURVIVAL BY ANTI-TAC, AN ANTI-HUMAN IL-2 RECEPTOR MONOCLONAL ANTIBODYTransplantation, 1989
- Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior UveitisOphthalmology, 1985
- Signs and Symptoms of Uveitis*American Journal of Ophthalmology, 1959